BLAINJECTIONINJECTABLEPriority Review
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
257
Data completeness
5/8 — Partial
Priority Review
IMFINZI (durvalumab) by AstraZeneca is programmed death ligand-1 antagonists [moa]. First approved in 2017.
Drug data last refreshed 14h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMFINZI (durvalumab) is a monoclonal antibody that blocks Programmed Death Ligand-1 (PD-L1), enabling the immune system to recognize and attack cancer cells. It is administered by injection and is indicated for multiple solid tumors where it enhances anti-tumor immunity. The drug represents a key checkpoint inhibitor in the immuno-oncology landscape.
$0.025BPart D
PeakIMFINZI is at peak commercial maturity with moderate Part D penetration; commercial teams are focused on market consolidation and defending against competitive incursion in the PD-L1 space.
Mechanism of Action
Programmed Death Ligand-1 Antagonists
Pharmacologic Class:
Programmed Death Ligand-1 Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (257)
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Started Jan 2027
50 enrolled
Extensive-stage Small-cell Lung Cancer
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Started Jan 2027
430 enrolled
Limited Stage Small-Cell Lung Cancer
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Started Nov 2026
50 enrolled
Extensive-stage Small-cell Lung Cancer
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Started Oct 2026
29 enrolled
Combined Hepatocellular and Cholangiocarcinoma
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC
Started Sep 2026
78 enrolled
Carcinoma, Non-Small-Cell Lung
Worked on IMFINZI at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.